IMO-3100: Completed Phase II enrollment

Idera completed enrollment of 44 patients in a placebo-controlled, double-blind, U.S. Phase II trial evaluating 0.16 and 0.32 mg/kg subcutaneous IMO-3100 once weekly for 4 weeks. ...